Do analysts prefer CARM or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate NCEL or EVGN?

NLS Pharmaceutics currently has a consensus target price of $23.00, suggesting a potential upside of 586.57%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, equities analysts clearly believe NLS Pharmaceutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, NCEL or EVGN?

NLS Pharmaceutics has higher earnings, but lower revenue than Evogene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Evogene $3.85M 1.36 -$8.48M -$1.39 N/A

Do analysts prefer EVGN or HOWL?

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 826.61%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Do analysts rate EVGN or NRSN?

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 1,775.97%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Does the media favor EVGN or NRSN?

In the previous week, Evogene and Evogene both had 5 articles in the media. Evogene's average media sentiment score of 1.62 beat NeuroSense Therapeutics' score of 0.37 indicating that Evogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PLUR or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, PLUR or EVGN?

Evogene has higher revenue and earnings than Pluri. Evogene is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 12.78 -$22.58M -$4.53 N/A Evogene $3.85M 1.36 -$8.48M -$1.39 N/A

Is PLUR or EVGN more profitable?

Evogene has a net margin of -638.12% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Evogene -638.12% -158.82% -80.37%

Evogene (EVGN) Competitors

$0.60 -0.05 (-7.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 +0.00 (+0.70%)

As of 07:24 PM Eastern

Compare

EVGN vs. CARM, NCEL, HOWL, NRSN, and PLUR

Should you buy Evogene stock or one of its competitors? Evogene's main competitors and comparable companies include Carisma Therapeutics (CARM), NLS Pharmaceutics (NCEL), Werewolf Therapeutics (HOWL), NeuroSense Therapeutics (NRSN), and Pluri (PLUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Evogene compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Carisma Therapeutics has a beta of -9.09, indicating that its share price is 1,009% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evogene had 5 more articles in the media than Carisma Therapeutics. MarketBeat recorded 5 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 1.62 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Very Positive

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.01	-$60.48M	$0.73	0.00
Evogene	$3.85M	1.36	-$8.48M	-$1.39	N/A

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-158.82%	-80.37%

Summary

Evogene beats Carisma Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Evogene compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

NLS Pharmaceutics has higher earnings, but lower revenue than Evogene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Evogene	$3.85M	1.36	-$8.48M	-$1.39	N/A

NLS Pharmaceutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

10.4% of Evogene shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NLS Pharmaceutics has a net margin of 0.00% compared to Evogene's net margin of -638.12%. NLS Pharmaceutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Evogene	-638.12%	-158.82%	-80.37%

NLS Pharmaceutics currently has a consensus target price of $23.00, suggesting a potential upside of 586.57%. Given NLS Pharmaceutics' stronger consensus rating and higher probable upside, equities analysts clearly believe NLS Pharmaceutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Evogene had 4 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 5 mentions for Evogene and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.87 beat Evogene's score of 1.62 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Very Positive
Evogene	Very Positive

Summary

NLS Pharmaceutics beats Evogene on 9 of the 13 factors compared between the two stocks.

How does Evogene compare to Werewolf Therapeutics?

Evogene (NASDAQ:EVGN) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

10.4% of Evogene shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evogene has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Evogene had 4 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for Evogene and 1 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.87 beat Evogene's score of 1.62 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evogene	Very Positive
Werewolf Therapeutics	Very Positive

Werewolf Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -638.12%. Evogene's return on equity of -158.82% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

Evogene has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.36	-$8.48M	-$1.39	N/A
Werewolf Therapeutics	$1.88M	10.46	-$60.82M	-$0.76	N/A

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 826.61%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Werewolf Therapeutics beats Evogene on 10 of the 16 factors compared between the two stocks.

How does Evogene compare to NeuroSense Therapeutics?

Evogene (NASDAQ:EVGN) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 1,775.97%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

In the previous week, Evogene and Evogene both had 5 articles in the media. Evogene's average media sentiment score of 1.62 beat NeuroSense Therapeutics' score of 0.37 indicating that Evogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NeuroSense Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.4% of Evogene shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evogene has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.36	-$8.48M	-$1.39	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

NeuroSense Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -638.12%. NeuroSense Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
NeuroSense Therapeutics	N/A	N/A	N/A

Summary

NeuroSense Therapeutics beats Evogene on 10 of the 15 factors compared between the two stocks.

How does Evogene compare to Pluri?

Pluri (NASDAQ:PLUR) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Pluri has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

16.6% of Pluri shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Evogene had 4 more articles in the media than Pluri. MarketBeat recorded 5 mentions for Evogene and 1 mentions for Pluri. Pluri's average media sentiment score of 1.89 beat Evogene's score of 1.62 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Very Positive
Evogene	Very Positive

Evogene has higher revenue and earnings than Pluri. Evogene is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	12.78	-$22.58M	-$4.53	N/A
Evogene	$3.85M	1.36	-$8.48M	-$1.39	N/A

Evogene has a net margin of -638.12% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Evogene	-638.12%	-158.82%	-80.37%

Summary

Evogene beats Pluri on 7 of the 13 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.24M	$3.71B	$6.97B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-0.43	10.68	269.86	25.30
Price / Sales	1.36	1,305.14	601.47	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.44	17.49	13.08	6.33
Net Income	-$8.48M	-$13.32M	$3.45B	$347.70M
7 Day Performance	0.12%	1.74%	1.12%	1.07%
1 Month Performance	24.36%	1.60%	1.79%	1.03%
1 Year Performance	-55.82%	56.43%	67.69%	20.77%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	1.7756 of 5 stars	$0.60 -7.7%	N/A	-51.1%	$5.24M	$3.85M	N/A	140	News Coverage Positive News Upcoming Earnings Insider Trade Short Interest Decrease
CARM Carisma Therapeutics	0.2606 of 5 stars	$0.00 flat	$1.00 +39,900.0%	-99.2%	$105K	$10.77M	0.00	20
NCEL NLS Pharmaceutics	2.8302 of 5 stars	$3.45 +0.9%	$23.00 +566.7%	-85.1%	$18.28M	N/A	N/A	6	Positive News Gap Down
HOWL Werewolf Therapeutics	3.1524 of 5 stars	$0.41 +12.8%	$3.75 +804.5%	-71.4%	$17.86M	$1.88M	N/A	40	Positive News Gap Up
NRSN NeuroSense Therapeutics	3.3547 of 5 stars	$0.52 +11.3%	$8.50 +1,534.9%	-64.6%	$17.64M	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, NCEL, HOWL, NRSN, and PLUR

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to NLS Pharmaceutics?

Summary

How does Evogene compare to Werewolf Therapeutics?

Summary

How does Evogene compare to NeuroSense Therapeutics?

Summary

How does Evogene compare to Pluri?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, NCEL, HOWL, NRSN, and PLUR

How does Evogene compare to Carisma Therapeutics?

Which has more risk and volatility, CARM or EVGN?

Do analysts prefer CARM or EVGN?

Do insiders and institutionals believe in CARM or EVGN?

Does the media prefer CARM or EVGN?

Which has higher valuation and earnings, CARM or EVGN?

Is CARM or EVGN more profitable?

Summary

How does Evogene compare to NLS Pharmaceutics?

Which has better earnings & valuation, NCEL or EVGN?

Which has more risk & volatility, NCEL or EVGN?

Do institutionals and insiders hold more shares of NCEL or EVGN?

Is NCEL or EVGN more profitable?

Do analysts rate NCEL or EVGN?

Does the media prefer NCEL or EVGN?

Summary

How does Evogene compare to Werewolf Therapeutics?

Do institutionals and insiders believe in EVGN or HOWL?

Which has more risk and volatility, EVGN or HOWL?

Does the media favor EVGN or HOWL?

Is EVGN or HOWL more profitable?

Which has higher valuation and earnings, EVGN or HOWL?

Do analysts prefer EVGN or HOWL?

Summary

How does Evogene compare to NeuroSense Therapeutics?

Do analysts rate EVGN or NRSN?

Which has more risk and volatility, EVGN or NRSN?

Does the media favor EVGN or NRSN?

Do insiders and institutionals have more ownership in EVGN or NRSN?

Which has higher valuation and earnings, EVGN or NRSN?

Is EVGN or NRSN more profitable?

Summary

How does Evogene compare to Pluri?

Which has more volatility and risk, PLUR or EVGN?

Do institutionals and insiders believe in PLUR or EVGN?

Do analysts prefer PLUR or EVGN?

Does the media refer more to PLUR or EVGN?

Which has higher earnings and valuation, PLUR or EVGN?

Is PLUR or EVGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools